Evidence map›Paper›PMID 36424380›Full record

ArticleScientific reports2022

Initial evaluation of extracorporeal immunomodulatory therapy for the treatment of critically ill COVID-19 infected patients.

Sandrine Lemoine, Jarrin Penny, Douglas D Fraser, Fabio R Salerno, Justin Dorie, Tanya Tamasi, Robert Arntfield, Andrew House, Marat Slessarev, Christopher W McIntyre

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Sandrine LemoineThe Lilibeth Caberto Kidney Clinical Research Unit (KCRU), Kidney Clinical Research Unit Room ELL-101, London Health Sciences, University of Western Ontario, Centre 800 Commissioners Rd E, London, ON, N6A5W9, Canada.
Jarrin PennyThe Lilibeth Caberto Kidney Clinical Research Unit (KCRU), Kidney Clinical Research Unit Room ELL-101, London Health Sciences, University of Western Ontario, Centre 800 Commissioners Rd E, London, ON, N6A5W9, Canada.
Douglas D FraserLawson Health Research Institute, London, ON, Canada.
Fabio R SalernoThe Lilibeth Caberto Kidney Clinical Research Unit (KCRU), Kidney Clinical Research Unit Room ELL-101, London Health Sciences, University of Western Ontario, Centre 800 Commissioners Rd E, London, ON, N6A5W9, Canada.
Justin DorieThe Lilibeth Caberto Kidney Clinical Research Unit (KCRU), Kidney Clinical Research Unit Room ELL-101, London Health Sciences, University of Western Ontario, Centre 800 Commissioners Rd E, London, ON, N6A5W9, Canada.
Tanya TamasiThe Lilibeth Caberto Kidney Clinical Research Unit (KCRU), Kidney Clinical Research Unit Room ELL-101, London Health Sciences, University of Western Ontario, Centre 800 Commissioners Rd E, London, ON, N6A5W9, Canada.
Robert ArntfieldLawson Health Research Institute, London, ON, Canada.
Andrew HouseDivision of Nephrology, Schulich School of Medicine & Dentistry, Western Ontario, London, Canada.
Marat SlessarevThe Lilibeth Caberto Kidney Clinical Research Unit (KCRU), Kidney Clinical Research Unit Room ELL-101, London Health Sciences, University of Western Ontario, Centre 800 Commissioners Rd E, London, ON, N6A5W9, Canada.
Christopher W McIntyreThe Lilibeth Caberto Kidney Clinical Research Unit (KCRU), Kidney Clinical Research Unit Room ELL-101, London Health Sciences, University of Western Ontario, Centre 800 Commissioners Rd E, London, ON, N6A5W9, Canada. cmcint48@uwo.ca.
Western University · CALondon Health Sciences Centre · CALawson Health Research Institute · CAVictoria Hospital · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe COVID-19 infection results in significant immune dysregulation resulting from excessive recruitment and activation of neutrophils. The aim of this study was to confirm feasibility, initial safety and detect signal of efficacy of a non-propriety device delivered using an intermittent extra-corporeal system (LMOD) allowing leucocytes modulation in the setting of Severe COVID-19 infection. Twelve patients were recruited. Inclusion criteria were > 18 years age, confirmed COVID-19, acute respiratory distress syndrome requiring mechanical support and hypotension requiring vasopressor support. Primary end point was vasopressor requirements (expressed as epinephrine dose equivalents) and principle secondary endpoints related to safety, ability to deliver the therapy and markers of inflammation assessed over five days after treatment initiation. LMOD treatment appeared safe, defined by hemodynamic stability and no evidence of white cell number depletion from blood. We demonstrated a significant decrease in vasopressor doses (-37%, p = 0.02) in patients receiving LMOD therapy (despite these patients having to tolerate an additional extracorporeal intermittent therapy). Vasopressor requirements unchanged/increasing in control group (+ 10%, p = 0.48). Although much about the use of this therapy in the setting of severe COVID-19 infection remains to be defined (e.g. optimal dose and duration), this preliminary study supports the further evaluation of this novel extracorporeal approach.

Indexed as

COVID-19 Drug TreatmentExtracorporeal Membrane OxygenationRespiratory Distress SyndromeCritical IllnessHumansImmunomodulationVasoconstrictor AgentsVasoconstrictor Agents

Identifiers

PMID36424380
PMCPMC9684905
OpenAlexW4310057544

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.